Sodium Fluoride f18- Sodium Fluoride F18 injection

Sodium Fluoride F-18 Injection, USP, is indicated for diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity.

• •Sodium Fluoride F-18 Injection, USP, emits radiation and must be handled with appropriate safety measures (
  2.1 Radiation Safety - Drug Handling

  • •Wear waterproof gloves and effective shielding when handling Sodium Fluoride F-18 Injection, USP. Use appropriate safety measures, including shielding, consistent with proper patient management to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel, and other persons.
  • •Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
  • •Use aseptic technique to maintain sterility during all operations involved in the manipulation and administration of Sodium Fluoride F-18 Injection, USP.
  • •The dose of Sodium Fluoride F-18 Injection, USP, should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed.
  • •The final dose for the patient should be calculated using proper decay factors from the time of End of Synthesis (EOS), and measured by a suitable radioactivity calibration system before administration [
    see Description
    ].
  ).
• •Administer 300-450 MBq (8–12 mCi) as an intravenous injection in adults (
  2.4 Recommended Dose for Adults

  Administer 300–450 MBq (8–12 mCi) as an intravenous injection.
  ).
• •Administer approximately 2.1 MBq/kg in children with a minimum of 19 MBq (0.5 mCi) and a maximum of 148 MBq (4 mCi) as an intravenous injection (
  2.5 Recommended Dose for Pediatric Patients

  In reported clinical experience in approximately 100 children, weight based doses (2.1 MBq/kg) ranging from 19 MBq–148 MBq (0.5 mCi–4 mCi) were used.
  ).
• •Imaging can begin 1–2 hours after administration; optimally at one hour post administration (
  2.7 Imaging Guidelines

  • •Imaging of Sodium Fluoride F-18 Injection, USP, can begin 1–2 hours after administration; optimally at 1 hour post administration.
  • •Encourage the patient to void immediately prior to imaging the fluoride F-18 radioactivity in the lumbar spine or bony pelvis.
  ).
• •Encourage patients to void immediately prior to imaging the lumbar spine and bony pelvis (
  2.7 Imaging Guidelines

  • •Imaging of Sodium Fluoride F-18 Injection, USP, can begin 1–2 hours after administration; optimally at 1 hour post administration.
  • •Encourage the patient to void immediately prior to imaging the fluoride F-18 radioactivity in the lumbar spine or bony pelvis.
  ).

Multiple-dose vial containing 370–7,400 MBq/mL (10–200 mCi/mL) at EOS reference time of no-carrier-added sodium fluoride F-18 in aqueous 0.9% sodium chloride solution. Sodium Fluoride F-18 Injection, USP, is a clear, colorless, sterile, pyrogen-free and preservative-free solution for intravenous administration.

• •Pregnancy: No human or animal data. Any radiopharmaceutical, including Sodium Fluoride F-18 Injection, USP, may cause fetal harm. Use only if clearly needed (
  8.1 Pregnancy

  Pregnancy Category C

  Any radiopharmaceutical including Sodium Fluoride F-18 Injection, USP, has a potential to cause fetal harm. The likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. Animal reproductive and developmental toxicity studies have not been conducted with Sodium Fluoride F-18 Injection, USP. Prior to the administration of Sodium Fluoride F-18 Injection, USP, to women of childbearing potential, assess for presence of pregnancy. Sodium Fluoride F-18 Injection, USP, should be given to a pregnant woman only if clearly needed.
  )
• •Nursing: A decision should be made whether to interrupt nursing after Sodium Fluoride F-18 Injection, USP, administration or not to administer Sodium Fluoride F-18 Injection, USP, taking into consideration the importance of the drug to the mother. (
  8.3 Nursing Mothers

  It is not known whether Sodium Fluoride F-18 Injection, USP, is excreted into human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of Sodium Fluoride F-18 Injection, USP, or not to administer Sodium Fluoride F-18 Injection, USP, taking into account the importance of the drug to the mother. The body of scientific information related to radioactivity decay, drug tissue distribution and drug elimination shows that less than 0.01% of the radioactivity administered remains in the body after 24 hours (10 half-lives). To minimize the risks to a nursing infant, interrupt nursing for at least 24 hours.
  )
• •Pediatrics: Children are more sensitive to radiation and may be at higher risk of cancer from Sodium Fluoride F-18 Injection, USP (
  8.4 Pediatric Use

  In reported clinical experience in approximately 100 children, weight based doses (2.1 MBq/kg) ranging from 19 MBq–148 MBq (0.5 mCi–4 mCi) were used. Sodium Fluoride F-18 was shown to localize to areas of bone turnover including rapidly growing epiphyses in developing long bones. Children are more sensitive to radiation and may be at higher risk of cancer from Sodium Fluoride F-18 Injection, USP.
  ).

• •Allergic Reactions: As with any injectable drug product, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available (
  5.1 Allergic Reactions

  As with any injectable drug product, allergic reactions and anaphylaxis may occur. Emergency resuscitation equipment and personnel should be immediately available.
  ).
• •Cancer Risk: Sodium Fluoride F-18 Injection, USP, may increase the risk of cancer. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker (
  5.2 Radiation Risks

  Sodium Fluoride F-18 Injection, USP, may increase the risk of cancer. Carcinogenic and mutagenic studies with Sodium Fluoride F-18 Injection, USP, have not been performed. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker [

  see Dosage and Administration

  ].
  ).